Blue Belt, a 6-year-old spin-off company from Carnegie Mellon University, is making a series of tools that rely on robotic technology and computer-assisted guidance for orthopedic and neurosurgery procedures. The company says its devices can automatically adjust the depth of a cut or disable the cut entirely based on the the location of the cut, and will help physicians make better cuts.

The company in July submitted its application to the U.S. Food and Drug Administration and in August closed on $750,000 in capital. This latest funding would be a catalyst to launch the technology.

Cognition Therapeutics focuses on detecting Abeta proteins, a protein found in Alzheimer’s patients that leads to the degeneration in the brain. The company is also developing molecules to block the proteins’ negative results and either stop or reverse Alzheimer’s. The company says its discoveries could also treat other neurodegenerative diseases.